A detailed history of Price T Rowe Associates Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 26,683 shares of TERN stock, worth $195,319. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,683
Previous 20,694 28.94%
Holding current value
$195,319
Previous $136,000 33.82%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.54 - $8.2 $27,190 - $49,109
5,989 Added 28.94%
26,683 $182,000
Q1 2024

May 15, 2024

BUY
$4.86 - $8.19 $10,988 - $18,517
2,261 Added 12.27%
20,694 $136,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $6.86 $2,180 - $4,438
647 Added 3.64%
18,433 $120,000
Q3 2023

Nov 14, 2023

BUY
$4.7 - $8.55 $3,760 - $6,840
800 Added 4.71%
17,786 $90,000
Q2 2023

Aug 14, 2023

BUY
$7.35 - $13.29 $124,847 - $225,743
16,986 New
16,986 $149,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $275M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.